Zhongchao (NASDAQ:ZCMD – Get Free Report) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued to investors on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings lowered Zhongchao from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, September 25th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has a consensus rating of “Sell”.
Read Our Latest Stock Analysis on ZCMD
Zhongchao Stock Performance
Shares of ZCMD opened at $1.02 on Friday. The company has a 50-day simple moving average of $1.59 and a two-hundred day simple moving average of $183.68. Zhongchao has a one year low of $1.02 and a one year high of $1,443.36.
Zhongchao Company Profile
Zhongchao Inc (NASDAQ: ZCMD) is a China-based healthcare services company focused on medical education and patient management. Through its operating subsidiaries, the company provides services intended to support healthcare professionals, patients and pharmaceutical or medical-product companies, with an emphasis on oncology and other chronic disease areas.
Zhongchao’s medical education activities have included online and offline educational programs, academic conferences, seminars and other professional training initiatives for physicians and healthcare providers.
Featured Articles
- Five stocks we like better than Zhongchao
- MarketBeat Week in Review – 10/26 – 10/30
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
Receive News & Ratings for Zhongchao Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhongchao and related companies with MarketBeat.com's FREE daily email newsletter.
